NSNicolás Lara Salas

Nicolás Lara Salas

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Nicolás Lara Salas has a total of 14 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Non-Coding RNA Biomarkers in Prostate Cancer: Evidence Mapping and In Silico Characterization

    by Lorena Albarracín-Navas, Nicolás I. Lara-Salas, Javier H. Alarcon-Roa, Maylin Almonte-Becerril, Enmanuel Guerrero, Ángela L. Riffo-Campos

    Non-coding RNAs (ncRNAs) have emerged as promising biomarkers for prostate cancer (PCa), yet evidence remains dispersed across heterogeneous studies and their regulatory context is seldom analyzed in an integrated manner. This study systematically maps ncRNAs reported as diagnostic biomarkers for PCa and characterizes their molecular interactions through in silico analyses. A comprehensive evidence-mapping strategy across major bibliographic databases identified 693 studies, of which 58 met eligibility criteria. Differentially expressed ncRNAs were extracted and classified by RNA type. Subsequently, miRNA–target prediction, miRNA–protein interaction network construction, and functional enrichment analyses were performed to explore the regulatory landscape of miRNA-associated proteins. Results: The final dataset included 4500 participants (2871 PCa cases and 2093 controls) and reported 94 differentially expressed miRNAs, eight lncRNAs, and several circRNAs, snoRNAs, snRNAs, and piRNAs. In silico analyses predicted 13,493 miRNA–mRNA interactions converging on 4916 unique target genes, with an additional 2481 prostate tissue-specific targets. The miRNA–protein network comprised 845 nodes and 2335 edges, revealing highly connected miRNAs (e.g., hsa-miR-16-5p, hsa-miR-20a-5p) and protein hubs (QKI, YOD1, TBL1XR1; prostate-specific CDK6, ACVR2B). Enrichment analysis showed strong overrepresentation of metabolic process-related GO terms and cancer-associated KEGG pathways. Conclusions: These findings refine the list of promising ncRNA biomarkers and highlight candidates for future clinical validation.

  • Open Access

    Non-Coding RNA Biomarkers in Prostate Cancer: Evidence Mapping and in Silico Characterization

    by Lorena Albarracín Navas, Nicolás Lara Salas, Javier Alarcón Roa, Maylin Almonte Becerril, Enmanuel Guerrero, Ángela Riffo Campos

    Background: Non-coding RNAs (ncRNAs) have emerged as promising biomarkers for prostate cancer (PCa), yet evidence remains dispersed across heterogeneous studies and their regulatory context is seldom analyzed in an integrated manner. This study systematically maps ncRNAs reported as diagnostic biomarkers for PCa and characterizes their molecular interactions through in silico analyses. Methods: A comprehensive evidence-mapping strategy across major bibliographic databases identified 693 studies, of which 58 met eligibility criteria. Differentially expressed ncRNAs were extracted and classified by RNA type. Subsequently, miRNA–target prediction, miRNA–protein interaction network construction, and functional enrichment analyses were performed to explore the regulatory landscape of miRNA-associated proteins. Results: The final dataset included 4,500 participants (2,871 PCa cases and 2,093 controls) and reported 94 differentially expressed miRNAs, eight lncRNAs, and several circRNAs, snoRNAs, snRNAs, and piRNAs. In silico analyses predicted 13,493 miRNA–mRNA interactions converging on 4,916 unique target genes, with an additional 2,481 prostate tissue–specific targets. The miRNA–protein network comprised 845 nodes and 2,335 edges, revealing highly connected miRNAs (e.g., hsa-miR-16-5p, hsa-miR-20a-5p) and protein hubs (QKI, YOD1, TBL1XR1; prostate-specific CDK6, ACVR2B). Enrichment analysis showed strong overrepresentation of metabolic process–related GO terms and cancer-associated KEGG pathways. Conclusions: These findings refine the list of promising ncRNA biomarkers and highlight candidates for future clinical validation.

  • Open Access

    Relación entre la puntuación de riesgo de diabetes finlandesa y el perfil lipídico en Ecuador. Estudio de corte transversal

    by Josué Rivadeneira-Dueñas, Luis Fuenmayor-González, Nancy Flores-Lastra, Pablo Herrera-Jumbo, Michelle Jácome-García, Luz Castillo, Raisa Tello-Cañar, María José Guerra-Tello, Thalía Fajardo-Loaiza, Javier Alarcón-Roa, et al.

    Introduction: Non-communicable diseases such as type 2 diabetes mellitus and dyslipidemias are highly prevalent in Ecuador. The Finnish Diabetes Risk Score (FINDRISC) measures the 10-year risk of developing diabetes, but its relationship with lipid profile has not been studied locally. This study examined the relationship between FINDRISC test results and total, HDL, and LDL cholesterol levels in Ecuadorian primary care patients. Objective: Analyze the relationship between the FINDRISC test score and lipid profile parameters in patients treated at primary care centers in Ecuador. Methods: A cross-sectional study was carried out in 236 adults without diabetes. The FINDRISC test score was calculated, and clinical and biochemical data were collected. Nonparametric tests were used to analyze correlations and differences between risk groups. Results: A moderate or higher risk of diabetes was present in 37.3% of participants. There were significant positive correlations between the FINDRISC score and both LDL (rho=0.37; p<0.001) and total cholesterol (rho=0.16; p=0.01). Intergroup differences were noted (p=0.04), but there was no correlation with HDL. Discussion: A higher FINDRISC score is associated with increased levels of total cholesterol and LDL, suggesting the tool may be useful for identifying broader metabolic risks beyond diabetes alone. While these findings align with existing research, the study's cross-sectional design and non-probabilistic sampling limit the ability to establish causality and generalize the results to the wider population. Conclusion: Higher LDL and total cholesterol levels are linked to increased FINDRISC scores. These findings support using the FINDRISC tool in primary care to identify broader metabolic risk